Clinical trial · Interventional
Therapy for Pediatric Hodgkin Lymphoma
Risk-Adapted Therapy for Pediatric Hodgkin's Disease
NCT00145600CI-TRIAL-00061596completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxicity. The main purpose of this study is to estimate the event free survival of patients treated with risk-adapted therapy compared to historical controls.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 12 Week Stanford V Chemotherapy | Drug | — | UNRESOLVED |
| 2 alternating cycles of VAMP/COP chemotherapy | Drug | — | UNRESOLVED |
| 3 alternating cycles of VAMP/COP chemotherapy | Drug | — | UNRESOLVED |
| 4 cycles of VAMP chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Unfavorable Risk, Group 2
- description
- Unfavorable risk, group 2 arm in patients with Hodgkin's disease (n=146)
- interventionNames
- Drug: 12 Week Stanford V Chemotherapy
- type
- EXPERIMENTAL
- label
- Favorable Risk
- description
- Favorable Risk arm in patients with Hodgkin's Disease (n=91).
- interventionNames
- Drug: 4 cycles of VAMP chemotherapy
- type
- EXPERIMENTAL
- label
- Intermediate Risk
- description
- Intermediate Arm in patients with Hodgkins's disease (n=46).
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria:
* Eligible patients must have histologically confirmed previously untreated Hodgkin's disease (Patients receiving limited emergent RT or steroid therapy because of cardiopulmonary decompensation or spinal cord compression will be eligible for protocol enrollment).
* Patients must be 21 years of age or younger
* Ann Arbor stages IIB-IV
* No prior treatment.
* No pregnant or lactating women.
* Signed informed consent
* If re-evaluation of a patient's disease shows favorable risk features or intermediate risk features, the patient will be removed from the HOD99 study and consented to the respective HOD08 or HOD05 study.
Inclusion: treatment of favorable risk features:
* Ann Arbor IA or IIA with:
1. Non-bulky mediastinal disease (\<33% mediastinal to thoracic ratio on chest x ray)
2. Ann Arbor stage IA or IIA with any of the following features: (1) "E" lesions (s), (2) 3 or more nodal sites involved, (3) Bulky mediastinal adenopathy (mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph)
Inclusion: unfavorable risk features:
* Stage must be classified as one of the following:
1. Ann Arbor stage IIB, IIIB, or any IVReferences
Publications (1)
- DERIVEDMetzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012 Jun 27;307(24):2609-16. doi: 10.1001/jama.2012.5847. PMID 22735430